Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 2/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863367 | 0.93 | TP53 (0.38) | TP53ACHEPER2CRY1CRY2 | |
| SCHEMBL774178 | 0.76 | ACHE (0.52) | TP53ACHEPSEN1PSEN2APH1B | |
| SCHEMBL29105338 | 0.74 | TP53 (0.36) | TP53ACHEPER2CRY1CRY2 | |
| SCHEMBL771715 | 0.74 | PSEN1 (0.39) | TP53ACHEPER2CRY1CRY2 | |
| SCHEMBL15379632 | 0.74 | NPSR1 (0.34) | TP53ACHEPER2CRY1CRY2 | |
| SCHEMBL14339172 | 0.72 | PER2 (0.35) | TP53ACHEPER2CRY1CRY2 | |
| SCHEMBL17327496 | 0.71 | ALDH1A1 (0.53) | ALDH1A1HTT | |
| SCHEMBL5658330 | 0.71 | PSEN1 (0.40) | TP53ACHEPER2CRY1CRY2 | |
| SCHEMBL14594697 | 0.71 | ALDH1A1 (0.53) | ALDH1A1HTT | |
| SCHEMBL9917271 | 0.71 | HSD11B1 (0.35) | TP53ACHEPER2CRY1CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | claimed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | claimed |
| EP-2501236-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-26 | — | — | EP | claimed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | claimed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-09-25 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2501236-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | TP53 559/4885ACHE 3981/4885PER2 3147/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | TP53 1820/4885ACHE 4110/4885PER2 1174/4885 |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | TP53 36/4885ACHE 1864/4885PER2 4746/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | TP53 559/4885ACHE 3981/4885PER2 3147/4885 |
| US-20140288070-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, KRAS, RAF1 | TP53 36/4885ACHE 1864/4885PER2 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.